Literature DB >> 19519293

Role of oxygen in cancer: looking beyond hypoxia.

Miguel López-Lázaro1.   

Abstract

Although cancer is considered to be a disease caused by DNA alterations, the high genetic variability of tumor cells makes it difficult to exploit these alterations for the treatment of cancer. The influence of non-genetic factors on cancer is increasingly being acknowledged and a growing line of research suggests that hypoxia (a decrease in normal oxygen levels) may play a fundamental role in the development of this disease. This line of research is supported by the fact that tumors often have hypoxic areas, that hypoxia activates the hypoxia-inducible factor 1 (HIF-1) and that HIF-1 activation plays a key role in cancer development. Evidence suggests, however, that the idea of hypoxia playing a central role in cancer development has some drawbacks. For instance, hypoxia has not been found in many tumors, HIF-1 activation has been observed in non-hypoxic tumor areas, and hypoxic tumor cells commonly have a reduced nutrient supply that restricts cell proliferation and tumor growth. This article reviews the literature that does not support the idea of hypoxia playing a central role in cancer development and discusses a broader view in which the role of oxygen in cancer is not limited to a reduction in its normal levels. According to this novel view, a deviation of the oxygen metabolism from the pathway that generates energy to the pathway that produces reactive oxygen species is crucial for cancer development. Interestingly, this switch in oxygen metabolism occurs under both hypoxic and normoxic conditions and may be exploited therapeutically.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519293     DOI: 10.2174/187152009788451806

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  8 in total

Review 1.  Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective.

Authors:  Francisco Javier Rodríguez-Jiménez; Victoria Moreno-Manzano
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

2.  HIF-1α genetic variants and protein expression confer the susceptibility and prognosis of gliomas.

Authors:  Liang Yi; Xuwei Hou; Ji Zhou; Lunshan Xu; Qing Ouyang; Hong Liang; Zhaocong Zheng; Hongjie Chen; Minhui Xu
Journal:  Neuromolecular Med       Date:  2014-06-15       Impact factor: 3.843

3.  Pd-porphyrin-cross-linked implantable hydrogels with oxygen-responsive phosphorescence.

Authors:  Haoyuan Huang; Wentao Song; Guanying Chen; Justin M Reynard; Tymish Y Ohulchanskyy; Paras N Prasad; Frank V Bright; Jonathan F Lovell
Journal:  Adv Healthc Mater       Date:  2013-11-20       Impact factor: 9.933

4.  Quantitative proteome analysis of pluripotent cells by iTRAQ mass tagging reveals post-transcriptional regulation of proteins required for ES cell self-renewal.

Authors:  Robert N O'Brien; Zhouxin Shen; Kiyoshi Tachikawa; Pei Angel Lee; Steven P Briggs
Journal:  Mol Cell Proteomics       Date:  2010-05-31       Impact factor: 5.911

Review 5.  A new view of carcinogenesis and an alternative approach to cancer therapy.

Authors:  Miguel López-Lázaro
Journal:  Mol Med       Date:  2009-12-28       Impact factor: 6.354

Review 6.  Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition.

Authors:  Colleen S Curran; Patricia J Keely
Journal:  Matrix Biol       Date:  2012-12-20       Impact factor: 11.583

Review 7.  Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and Cancer.

Authors:  Elena Talero; Sofía García-Mauriño; Javier Ávila-Román; Azahara Rodríguez-Luna; Antonio Alcaide; Virginia Motilva
Journal:  Mar Drugs       Date:  2015-09-30       Impact factor: 5.118

8.  Gloeothece sp.-Exploiting a New Source of Antioxidant, Anti-Inflammatory, and Antitumor Agents.

Authors:  Helena M Amaro; Rita Barros; Tânia Tavares; Raquel Almeida; Isabel Sousa Pinto; Francisco Xavier Malcata; Ana Catarina Guedes
Journal:  Mar Drugs       Date:  2021-11-04       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.